Page last updated: 2024-10-26

diphenhydramine and Soft Tissue Neoplasms

diphenhydramine has been researched along with Soft Tissue Neoplasms in 2 studies

Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.

Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.

Research Excerpts

ExcerptRelevanceReference
"Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week."6.71Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). ( Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003)
"Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week."2.71Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). ( Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sato, K1
Inoue, K1
Saito, T1
Kai, T1
Mihara, H1
Okubo, K1
Koh, J1
Mochizuki, H1
Tabei, T1
Casper, ES1
Cordon-Cardo, C1
Houghton, AN1
Steffens, TA1
McCormack, P1
Magill, GB1
Hajdu, SI1
Brennan, MF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890]89 participants (Actual)Observational2004-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for diphenhydramine and Soft Tissue Neoplasms

ArticleYear
Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:8

    Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethaso

2003
Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma.
    Cancer investigation, 1994, Volume: 12, Issue:1

    Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Diphenhydramine; Epinephrine;

1994